Study: NCT02478398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Short ragweed pollen allergen extract
Description: One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo sublingual tablet, QD for up to 35 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Self-injectable epinephrine
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-injectable epinephrine
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine
Description: Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate monohydrate
Description: Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate
Description: Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms